AI-generated summary
The authors report an open-label pilot study of two photobiomodulation devices, a transcranial helmet and a whole-body light bed, in two groups of seven people with post-COVID-19 brain fog. After 12 treatments over four weeks, both devices were associated with significant improvements in cognitive tests, and EEG changes were reported to support these findings. The study was small and open-label, so its results are preliminary.
- Who or what was studied
- Adults with post-COVID-19 brain fog (long COVID), in two groups of seven
- Wavelengths
- 1070, 660, 850 nm
- Limits stated in the abstract
- Small open-label pilot study with two groups of seven and no reported control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1070 nm, 850 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Brain fog, Montreal Cognitive Assessment, Transcranial photobiomodulation, Electroencephalography. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.